MoneyWorks4Me

Novartis India Ltd (NOVARTIND)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500672 NSE: NOVARTIND Trading | Small Cap | Novartis India Share Price

₹2,048.65 -140.90 (-6.44%)

As on 16-Sep'26 10:05

Novartis India Ltd (NOVARTIND)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500672 NSE: NOVARTIND Trading | Small Cap | Novartis India Share Price

₹2,048.65 -140.90 (-6.44%)

As on 16-Sep'26 10:05

Key Metrics
Valuation Multiples
Market Cap
₹5,406 Cr.
Current Price
₹2,048.7
52-Week Low / High
₹750 / 2,588
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
38.9
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
6.33%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
70.68%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹12.4 Cr.
Face Value
₹5
All Time Low / High
₹65.00 / 2588.00

Novartis India stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Overvalued

Price Trend

Strong
Q.1 Is Novartis India Ltd a good quality company?
Novartis India Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Novartis India Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Novartis India Ltd vs industry peers?
Novartis India Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Q.1 Promoter shareholding and pledge status of Novartis India Ltd?
Promoters hold 70.68% of the Novartis India Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Novartis India Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 11.7% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Novartis India Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 24.8%8.8%19.7%11.7%4.7%6.7%0.1%16%16.4%17.2%-
Value Creation
Index
0.8-0.40.4-0.2-0.7-0.5-1.00.10.20.2-

Growth Parameters

Sales 690656564491438381400379335356371
Sales YoY Gr.--4.9%-14.1%-13%-10.7%-13%4.9%-5.3%-11.5%6.3%-
Adj EPS 62.120.231.8224.68.512.642.134.640.939.6
YoY Gr.--67.5%57.7%-31%-78.9%82.5%48.4%234.8%-17.8%18.3%-
BVPS (₹) 375.6329.5299.8309.3293.4289.4281.2314.3301.8318.1344.3
Adj Net
Profit
19956.878.654.211.520.93110485.410198
Cash Flow from Ops. 56.6-40.8161-194-23.1-69.238.744.811374.6-
Debt/CF from Ops. 0000000000-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales -7.1%-4.1%-3.8%6.3%
Adj EPS -4.5%54.6%48.2%18.3%
BVPS-1.8%1.6%4.2%5.4%
Share Price 10.9% 19.6% 39.9% 127.2%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
18.15.49.57.31.62.94.414.211.213.212
Op. Profit
Mgn %
4.63.7-1.43.23.16.86.717.519.625.727.5
Net Profit
Mgn %
28.88.713.911.12.65.57.827.425.528.426.4
Debt to
Equity
0000000000-
Working Cap
Days
4294606888439781,2471,1641,2991,3601,176380
Cash Conv.
Cycle
3026-7-20-5481-4-7310

Valuation of Novartis India - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

data not found
No data found!
data
No data found!
data
No data found!
data
No data found!

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Novartis India Ltd FAQs

The current trading price of Novartis India on 16-Sep-2026 10:05 is ₹2,048.7.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 15-Sep-2026 the market cap of Novartis India stood at ₹5,406.2 Cr

The latest P/E ratio of Novartis India as of 15-Sep-2026 is 55.29.

The latest P/B ratio of Novartis India as of 15-Sep-2026 is 6.36.

The 52-week high of Novartis India is ₹2,588 and the 52-week low is ₹750.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Novartis India is ₹371 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Novartis India Ltd is a below average quality company.

The key valuation ratios of Novartis India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Novartis India Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Novartis India Ltd

Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. From beginnings in the production of synthetic fabric dyes, the companies that eventually became Novartis branched out into producing chemicals and ultimately pharmaceuticals.

The history of Novartis traces the converging destinies of three companies: Geigy, a chemicals and dyes trading company founded in Basel, Switzerland in the middle of the 18th century; Ciba, which began producing dyes in 1859; and Sandoz, a chemical company founded in Basel in 1886.

These companies shared a common trait which lives on at Novartis: a passion for developing and marketing new products that contribute to human progress through advances in science and health. Building on this heritage, today Novartis focuses its innovation prowess on addressing the unmet needs of patients worldwide.

Since 1947, Novartis has had a significant footprint in India - committed to drug development, manufacturing, commercial and social business services. It has three legal entities namely, Novartis Healthcare Private Limited, Novartis India Limited and Sandoz Private Limited employing thousands of people. It has a rich portfolio of both innovative and established medicines addressing various therapeutic needs: cardiovascular, eye care, immunology and dermatology, metabolics, neuroscience, oncology, respiratory and organ transplant, to meet the medical needs of patients in India.

Its social business -- Arogya Parivar -- is expanding access to community education, improved infrastructure and affordable healthcare products for underserved populations in rural India.

The company’s purpose is to reimagine medicine to improve and extend people’s lives. It uses innovative science and technology to address some of society’s most challenging healthcare issues. It discover and develops breakthrough treatments and find new ways to deliver them to as many people as possible. It also aims to reward those who invest their money, time and ideas in the company.

Business area of the company

As a science-based and patient-oriented healthcare company, it strives to be a global leader in growing areas of healthcare. Following a corporate transformation Novartis globally is focused on three divisions with global scale and innovation power - pharmaceuticals, eye care and generic medicines. This has strengthened the future growth prospects of the company.

In India, the Pharmaceutical business of Novartis India Limited is focused on Bone & Pain, Calcium portfolio, Gynecology and Neurosciences and the Generics business is focused on Gynecology, Anti-TB and Anti-infectives.

You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now